Development · 21 Aug 2026
MANKIND, full dossier1 publisher has reported this development. Each act of reporting is below, cited.
Mankind Pharma entered into an exclusive in-licensing and marketing agreement with China's Chongqing Chenan Biopharmaceutical to commercialise two insulin analogues (insulin degludec and insulin degludec in combination) in India for diabetes care.
A single act of reporting so far, corroborating sources join this record as they publish.
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.